Glad you brought it up: A patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice

Quality in Primary Care

Volumn 20, Issue 2, 2012, Pages 141-148

  MUrie, Jill ^a   Allen, Jane ^b   Simmonds, Ray ^b   De Wet, Carl ^a  

^a Kingshill Medical Practice   (United Kingdom)

^b Pharmexx Alchemy ^*  (United Kingdom)

Author keywords

Alginate; Gastro oesophageal reflux; General medical practice; Non ulcer dyspepsia; Primary care; Proton pump inhibitor

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; FEMALE; GENERAL PRACTICE; HUMAN; MALE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PATIENT EDUCATION; PROSPECTIVE STUDY; QUESTIONNAIRE; SELF CARE; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENERAL PRACTICE; HUMANS; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PATIENT-CENTERED CARE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; QUESTIONNAIRES; SCOTLAND; SELF CARE;

EID: 84862013434     PISSN: 14791072     EISSN: 14791064     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. NHS Information Centre. Prescribing Cost Analysis, England, 2011. www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/ prescription-costanalysis-england-2010 (accessed 30/06/11).
2. Information Services Division S. Prescription Cost Analysis, 2011. www.isdscotland.org/Health-Topics/Prescribingand-Medicines/Community-Dispensing/ PrescriptionCost-Analysis (accessed 30/06/11).
3. Forgacs I and Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008 Jan 5;336(7634):2-3.
4. Zink DA, Pohlman M, Barnes M and Cannon ME. Longterm use of acid suppression started inappropriately during hospitalization. Alimentary Pharmacology & Therapeutics 2005 May 15;21(10):1203-9. (Pubitemid 40733485)
5. Dent J, El-Serag HB, Wallander MA and Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 May;54(5):710-17. (Pubitemid 40559260)
6. Dillon J. Gastric acid should not be the only target of therapeutic strategies in primary care. Gastroenterology Today 2004;13(3):l-4.
7. Fass R, Shapiro M, Dekel R and Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Alimentary Pharmacology & Therapeutics 2005 Jul 15;22(2):79-94. (Pubitemid 41039696)
8. Raghunath AS, Hungin AP, Mason J and Jackson W. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. Alimentary Pharmacology & Therapeutics 2009 Feb 15;29(4):431-9.
9. Reimer C and Bytzer P. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis of 901 patients. Alimentary Pharmacology & Therapeutics 2009 Oct;30(7):725-32.
10. Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Archives of Internal Medicine 2010 May 10; 170(9) :747-8.
11. Yang YX, Lewis JD, Epstein S and Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. Journal of the American Medical Association 2006 Dec 27;296(24):2947-53. (Pubitemid 46021498)
12. Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Archives of Internal Medicine 2010 May 10;170(9):765-71.
13. Rodriguez LA, Ruigomez A, Wallander MA and Johansson S. Acid-suppressive drugs and communityacquired pneumonia. Epidemiology 2009 Nov;20(6): 800-6.
14. Myles PR, Hubbard RB, McKeeverTM, Pogson Z, Smith CJ and Gibson JE. Risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiology & Drug Safety 2009 Apr; 18(4): 269-75.
15. Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR and Louie TJ. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Alimentary Pharmacology & Therapeutics 2009 Mar 15;29(6):626-34.
16. National Institute for Health and Clinical Excellence. Dyspepsia: managing dyspepsia in adults in primary care, 1 August 2004, pp. 1-228. Available at: www.nice. org.uk/nicemedia/live/10950/29459/29459.pdf (accessed 29/03/12).
17. Scottish Intercollegiate Guidelines Network. Dyspepsia: a National Clinical Guideline. 2003, pp. 1-30. Available at: www.sign.ac.uk/pdf/sign68.pdf (accessed 29/03/12).
18. Lee TJ, Fennerty MB and Howden CW. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Alimentary Pharmacology & Therapeutics 2004 Dec;20(11-12):1241-51.
19. Pace F, Tonini M, Pallotta S, Molteni P and Porro GB. Systematic review: maintenance treatment of gastrooesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Alimentary Pharmacology & Therapeutics 2007Jul 15;26(2):195-204. (Pubitemid 46985505)
20. Evans N, Holmes J, Rawaf S and Dawson S. Dyspepsia and GORD care after PPI use. British Journal of Healthcare Management 2007; 13(11) :425-30.
21. Cawston J and Evans N. Dyspepsia: key considerations for cost-effective management. Prescriber 2007 Mar 5:1-7.
22. Inadomi JM, Jamal R, Murata GH et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001 Nov;121(5):1095-100. (Pubitemid 33022089)
23. Cote GA, Ferreira MR, Rozenberg-Ben-Dror K and Howden CW. Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. Alimentary Pharmacology & Therapeutics 2007 Mar 15;25(6):709-14.
24. Krol N, Wensing M, Haaijer-Ruskamp F et al. Patientdirected strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Ali-mentary Pharmacology &Therapeutics 2004 Apr 15; 19(8):917-22.
25. Hunfeld NG, Geus WP and Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Alimentary Pharmacology & Therapeutics 2007 Jan 1;25(1):39-46.
26. Gillen D, Wirz AA and McColl KEL. Rebound maximal acid hypersecretion after Omeprazole persists to at least 11 months after treatment. Gut;2001;48(Suppl I):A8.
27. Bjornsson E, Abrahamsson H, Simren M et al. Discontinuation of proton pump inhibitors in patients on longterm therapy: a double-blind, placebo-controlled trial. Alimentary Pharmacology & Therapeutics 2006 Sep 15; 24(6):945-54. (Pubitemid 44326375)
28. Dibley LB, Norton C and Jones R. Non-pharmacological intervention for gastro-oesophageal reflux disease in primary care. British Journal of General Practice 2010 Dec;60(581):e459-65.
29. Barlow J, Wright C, Sheasby J, Turner A and Hainsworth J. Self-management approaches for people with chronic conditions: a review. Patient Education and Counseling 2002;48(2): 177-87. (Pubitemid 36158880)